NyQuil

The next chapter in the Valeant Pharmaceuticals Intl Inc (NYSE: VRX) story began today when the company named Joseph Papa as its new CEO. Shareholders are hoping that Papa can right the ship after a whirlwind of controversy has driven Valeant’s share price down 63.1 percent so far in 2016...